• Allotera Therapeutics

  Participated · Series C · Jul 2026

  Allotera Therapeutics (formerly Wugen) is advancing Soficabtagene Geleucel (Sofi-cel), a CD7-targeted allogeneic, off-the-shelf CAR-T cell therapy for T-cell malignancies. Sofi-cel is manufactured from healthy donor T cells in the United States and uses CRISPR/Cas9 to delete CD7 and TRAC to reduce fratricide and graft-versus-host disease risk. Sofi-cel is being evaluated in a global pivotal T-RRex clinical trial for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma (ClinicalTrials.gov identifier NCT06514794). The therapy has received multiple regulatory designations, including Breakthrough Therapy, RMAT, Fast Track, Orphan Drug, Rare Pediatric Disease in the U.S., and PRIME in the EU. The company says its approach aims to address biological and manufacturing barriers in T-cell CAR-T development and is using recent financing to support pivotal development, manufacturing scale-up, platform advancement, and team growth. Allotera is headquartered in St. Louis.

• AI Proteins

  Participated · Series A · Nov 2025

  AI Proteins has built an AI-enabled discovery platform that designs and optimizes de novo miniproteins, giving the company precise control over molecular function, stability, and pharmacology. The platform’s industrialized design-build-test cycle has already produced molecules against more than 150 targets and delivered multiple in-vivo proof-of-concepts. In December 2024 the company entered a research collaboration and option agreement with Bristol Myers Squibb worth up to $400 million, validating commercial interest in its technology. Beyond internal drug programs, the modular miniproteins can be applied to diagnostics, agriculture and research reagents. To scale efficiently, AI Proteins is adopting a hub-and-spoke LLC structure that spins individual programs into subsidiaries while preserving the core platform. The new capital will bolster platform expansion, data generation, and advancement of lead therapeutic candidates toward IND-enabling studies. The company’s investors believe the approach could usher in a new class of protein medicines that outperform traditional antibodies.

• Predicta Biosciences

  Participated · Series A · Oct 2025

  Predicta Biosciences builds laboratory-developed tests that combine deep genomic and immune profiling to improve the diagnosis and management of blood cancers such as multiple myeloma. Its first product, GenoPredicta, launched in April and can be run on either peripheral blood or bone marrow to help physicians identify molecular drivers of disease and predict patient response to immunotherapies like CAR-T cells and bispecific antibodies. The company operates a CLIA-approved laboratory and plans to use new capital to expand both its team and lab infrastructure. Beyond diagnostics, Predicta intends to leverage its growing dataset to discover and commercialize precision therapeutics. The firm collaborates with clinical providers and advocacy groups, including the HealthTree Foundation, to accelerate adoption. Brian McKernan, a three-time biotech founder and former CEO of Fluent BioSciences, has been appointed CEO to steer commercialization and future product development. Financial metrics such as revenue or user numbers were not disclosed in the article.

• Geneoscopy

  Participated · Series C · Jan 2025

  Geneoscopy leverages a proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform to develop diagnostic tests for gastrointestinal diseases. Its lead product, ColoSense, is an FDA-approved at-home, stool-based colorectal cancer screening test for average-risk individuals over age 45. The company pairs its RNA isolation platform with Bio-Rad’s Droplet Digital PCR (ddPCR) technology to achieve high sensitivity and specificity. Geneoscopy plans to launch and commercialize ColoSense and is working with Labcorp to provide broad availability so providers can order the test within screening programs. The firm is also investing in an innovative pipeline of diagnostic tests for inflammatory bowel disease, including tools for treatment selection and therapy monitoring. The recent financing is positioned to support commercialization, regulatory milestones, and continued product development. Geneoscopy is a St. Louis, MO–based life sciences company focused on developing diagnostic tests for gastrointestinal health. Its lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. The device was awarded Breakthrough Device Designation from the US FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Preliminary trials suggest the diagnostic can detect these lesions at a higher rate than existing noninvasive screening tests. The company intends to use recent funding to support the U.S. CRC-PREVENT pivotal trial, scale commercial infrastructure, and expand its diagnostic product pipeline. Andrew Barnell is the company's CEO. Geneoscopy is a life sciences company focused on developing diagnostic tests for gastrointestinal (GI) health. Its lead product is a colorectal cancer (CRC) screening test that quantifies eukaryotic RNA isolated from epithelial cells in stool to detect CRC and advanced adenomas. The company announced an oversubscribed $6.9 million Series A and plans to use the proceeds to advance the CRC screening test. The financing was led by Cultivation Capital and NT Investments, with Lightchain Capital LLC as a significant investor. Following the round, Bobby W. Sandage, Jr., Najeeb Thomas, and Drew Dennison are joining Geneoscopy’s board of directors. Geneoscopy highlights that stool-derived eukaryotic RNA biomarkers are highly sensitive for both cancer and precancerous lesions, and it intends to pursue other applications of its platform technology.

• NextRNA Therapeutics

  Led · Series A · Mar 2022

  NextRNA Therapeutics leverages a proprietary discovery platform to systematically identify disease-relevant long non-coding RNAs and their interacting proteins and to develop selective small molecules that modulate those interactions. The company is advancing a pipeline built from that platform and has progressed two small-molecule programs in oncology and immunology. NextRNA was founded in January 2021 and is based in Cambridge, Massachusetts. Leadership and scientific founders include Carl Novina and Robert Langer, and the company cites pioneering work at Dana-Farber Cancer Institute as its scientific basis. At launch NextRNA intends to use financing proceeds to augment its target and drug discovery engine, expand its pipeline, and advance lead programs. The company positions itself to translate discoveries around long non-coding RNAs into transformative therapies across multiple disease areas.

No current team members are available.